Five things to know:
1. Stryker reported net sales increased 9.9 percent to $3.7 billion. Orthopedics sales were up 3.7 percent to $1.3 billion while spine and nanotechnology jumped 18.9 percent to $800 million. For the six months end, overall sales were up 9.2 percent to $7.1 billion
2. Net earnings hit $480 million for the quarter, up 6.2 percent compared to the same period last year.
3. U.S. sales for the second quarter were up 13 percent overall, hitting $2.7 billion. International sales were up slightly, 1.9 percent, to $955 million.
4. Knee sales were up 4.2 percent to $440 million while hip sales grew just 1.9 percent to $343 million. Trauma and extremities sales were up 2 percent to $394 million and spine sales increased 37.5 percent to $277 million, post-K2M acquisition.
5. Stryker expects full year organic net sales to increase 7.5 percent to 8 percent. Projected adjusted net earnings per share are $8.15 to $8.25 for the full year.
More articles on orthopedic devices:
Life Spine receives FDA clearance for expandable spacer implant
Medtronic, Alphatec & more: 7 device company notes
15 spine devices receive FDA 510(k) clearance in June
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
